Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 5 April

Sophia Mavridis
April 5, 2022

Morning Bell 4 April

Sophia Mavridis
April 4, 2022

Weekly Wrap 1 April

Sophia Mavridis
April 1, 2022

Morning Bell 31 March

Paulina Peters
March 31, 2022

Morning Bell 30 March

Sophia Mavridis
March 30, 2022

Morning Bell 29 March

Paulina Peters
March 29, 2022

Morning Bell 28 March

Sophia Mavridis
March 28, 2022

Weekly Wrap 25 March

Sophia Mavridis
March 25, 2022

Morning Bell 24 March

Sophia Mavridis
March 24, 2022

Morning Bell 23 March

Paulina Peters
March 23, 2022

Morning Bell 22 March

Paulina Peters
March 22, 2022